What occurred

Shares of Invitae Company (NVTA 11.57%) closed 11.57% increased on Friday after Cathie Wooden, the CEO of Ark Make investments, stated the inventory was undervalued. Wooden’s Ark Innovation ETF owns greater than 18 million shares of Invitae, value roughly $24 million as of Friday, so her firm has an enormous stake within the inventory, which has declined greater than 74% over the previous 12 months and greater than 27% up to now this 12 months.

So what

Invitae makes a speciality of genetic testing to enhance healthcare outcomes. The corporate completed 2022 with improved income, nevertheless it had big losses. The corporate reported 2022 income of $516.3 million, up 12.1%. Nevertheless, it misplaced $3.1 billion, or $13.18 in earnings per share (EPS), in comparison with a lack of $379 million and an EPS lack of $1.80 in 2021. The corporate additionally has round $1.6 billion in web debt, in order that’s a giant concern. 

Now what

The corporate has begun cost-cutting measures. Within the fourth-quarter earnings name, Chief Monetary Officer Roxie Wen stated the corporate expects to scale back its money burn in 2023 to $250 to 275 million in 2023, a greater than 45% discount from the almost $510 million in money burn the corporate had in 2022. Nonetheless, the inventory presents lots of danger to buyers, with its massive debt load. The corporate did present some progress within the fourth quarter, with its web loss being $99.8 million, in comparison with a $205 million loss in the identical interval final 12 months. In the long term, genetic testing has loads of development potential. A report by Grand View Analysis estimates the genetic testing market at $8.8 billion in 2023. It’s anticipated to have a compound annual development charge of twenty-two% between now and 2030, reaching a $35.34 billion market by that point. The query can be whether or not Invitae can be round for that development.